Home India Ministry of Health and Family Welfare State NSQ ALERT FOR THE MONTH OF JUNE 2024...
Date: 2024-07-19 Category: Not Applicable State: Union Government Country: India

State NSQ ALERT FOR THE MONTH OF JUNE 2024

Issued by Ministry of Health and Family Welfare · Central Drugs Standard Control Organization

Research with AI Agent Chat with Document Generate Summary Translate Helpful Share Add to Project Create Task

Executive Summary & Key Takeaways

Key Changes

  • Several State Drugs Licensing Authorities did not submit any data for June 2024.
  • A total of 30 products are listed as Not of Standard Quality (NSQ).
  • Failures were reported by Drugs Testing Laboratories in Thiruvananthapuram and Maharashtra.
  • Common reasons for failure include not meeting requirements for Dissolution, Assay, pH, Alcohol soluble extractive, Descriptive part of hard gelatin capsules, Total Aerobic Viable Count, Content of Montelukast and Levocetirizine, Related Substances – Rosuvastatin.
  • Products manufactured by various companies including Kerala State Drugs & Pharmaceuticals Ltd, Hindustan Antibiotics Ltd, Lividus Pharmaceuticals pvt.Ltd, Zenith Healthcare Ltd, Glenmark Pharmaceuticals Ltd, Sterlife Pharma Pvt. Ltd., Torque Pharmaceuticals Pvt. Ltd., Ticoma Pharmacia, Bajaj Formulations, Amentis Biotech Pvt. Ltd., Cosway Pharmaceuticals, SVR Healthcare, Alicon Pharmaceutical Pvt Ltd, Addii Biotech Pvt. Ltd., Ultra Drugs Pvt. Ltd., Salus Pharmaceuticals, Iosis Remedies Pvt. Ltd., Leeford Healthcare Ltd., Elfin Drugs Pvt. Ltd., Evolet Pharmaceutical Pvt. Ltd., Anrose Pharma, Abaris Healthcare, Tulbros Formulations, White Engle Laboratories, Cent Cure Pvt Ltd, Pure & Care Healthcare Pvt. Ltd. are listed.
  • Specific products failing tests include Liquid Paraffin IP, Losartan Potassium Tablets IP 50 mg, Amlodipine Besylate and Atenolol Tablets, Cefpodoxime Proxetil Tablets USP, Oseltamivir Cap IP 75 mg, Haridrakhandam, Yogarajaguggulu, Itraconazole Capsule B.P. 100 MG, Itraconazole Capsules 200 mg, Montelukast Sodium & Levocetrizine Dihydrochloride Tablet I.P., Montelukast & Levocetirizine Hydrochloride Tablets, Levocetrizine Dihydrochloride & Montelukast Sodium Tablets I.P., VolKast Kid Syrup 60 ml., Levetiracetam Tablets U.S.P.500 Mg, Pantoprazole Gastro-resistant & Domperidone Prolonged-release Capsules IP, Omeprazole - 40, Omeprazole with Domperidone Capsules, Pantoprazole Gasto-resistant & Domperidone Prolonged-release Capsules IP, Omeprazole and Domperidone Capsules IP, Pantoprazole (EC) & Domperidone (SR) Capsules IP, aluminium, magnesium & simethicone oral suspension IP., Azithromycin oral suspension IP 15ML, Alprazolam Tablets, Rabeprazole Sodium Tablets IP, PARACETAMOL TABLETS I.P. 650 mg, Pantoprazole, Pantoprazole Gastro-resistant Tablets IP, Rosuvastatin Capsules.
  • The alert notes that NSQ data was not received in the correct format from Rajasthan and Orissa.

What it means

  • This is a Not of Standard Quality (NSQ) alert issued for the month of June 2024, identifying drugs and pharmaceutical products that failed quality tests conducted by various state laboratories and CDSCO laboratories.
  • The alert lists the name of the drug/product, batch number, manufacturing and expiry dates, manufacturer, the reason for failure, and the reporting laboratory.

Impact Analysis

Manufacturers

  • A review of manufacturing processes, quality control procedures, and raw material sourcing is recommended.

Distributors and Retailers

  • Coordination with manufacturers and regulatory authorities is crucial for the smooth execution of recall procedures.

Consumers/Patients

  • Increased awareness among consumers about drug quality and reporting mechanisms is necessary.

Regulatory Authorities (State and Central)

  • The DCG(I) should address the issue of non-reporting of NSQ data by some states to ensure comprehensive monitoring.

Key Entities Referenced

CDSCO: Central Drugs Standard Control Organization, the national regulatory body for pharmaceuticals and medical devices in India. State Drugs Licensing Authorities: State-level regulatory bodies responsible for licensing and monitoring pharmaceutical manufacturing and sales within their respective states. IP: Indian Pharmacopoeia, the official book of standards for drugs manufactured and marketed in India. USP: United States Pharmacopeia BP: British Pharmacopoeia Drugs and Cosmetics Act 1940: Indian law that regulates the import, manufacture, distribution, and sale of drugs and cosmetics. Drugs and Cosmetics Rules 1945: Rules framed under the Drugs and Cosmetics Act 1940 to regulate the import, manufacture, distribution, and sale of drugs and cosmetics. DCG(I) Circular dated 09.02.2024: Circular issued by the Drugs Controller General of India regarding the reporting of Not of Standard Quality (NSQ) data.
Official Source Record View Original Source →
See Full Document Text
NOT OF STANDARD QUALITY ALERT FOR THE MONTH OF JUNE – 2024. B. State Laboratories S.No Product/Drug Batch No. Manufacturing Expiry Manufactured By NSQ Result Reported by Name Date Date CDSCO Laboratory 1. Liquid Paraffin IP EP4032 01/24 12/26 Repacked by :- Kerala State It fails the test Drugs Testing Drugs & Pharmaceuticals light absorption Laboratory Ltd, Kalavoor.P.O, as per IP Thiruvananthapura Alappuzha m 2. Losartan HLOA06 11/23 10/25 Hindustan Antibiotics It fails the test Drugs Testing Potassium Tablets Ltd, at II, W.E.A, ‘Dissolution’ as Laboratory IP 50 mg Faridabad- 121 per IP Thiruvananthapura 001(Haryana) R.O, m Pimpri, Pune -411 018 3. Amloheart-AT LE223030 03/23 02/25 Lividus Pharmaceuticals Drugs Testing [Amlodipine pvt.Ltd, ikeva, Level2, It fails the test Laboratory Besylate and Agnito Tech park,141 ‘Assay’ of Thiruvananthapura Atenolol Tablets] Kandachavadi, Near, Amlodipine m Perungudi, OMR, Besylate Chennai-600096 4. Bacotil-200 ZTB-148 03/24 02/26 Zenith Healthcare Ltd It fails the test Drugs Testing [Cefpodoxime works: 388/34, ‘Dissolution’ as Laboratory Proxetil Tablets Changodarlnd. Estate, per USP Thiruvananthapura USP ] Sarkhej Bavla Highway, m Changodar- 382213 (Gujarat) 5. Oseltamivir Cap D 0444/24- Supplied by Kerala The sample does Drugs Testing IP 75 mg 25 Medical Services not conform to IP LaboratoryCorporation Ltd, standard with Thiruvananthapura Thycaud P.O, respect to the m Thiruvananthapuram-14 ‘Descriptive part’ of hard gelatin capsules 6. Haridrakhandam 207/23 03/24 02/26 Bhaskaravilasam It fails the test Drugs Testing Vaidyasala, ‘pH’ as per API Laboratory Panayamuttom, Thiruvananthapura Nedumangadu m Thiruvananthapuram 695 561 7. Yogarajaguggulu 209/21 03/22 3 yrs from Bhaskaravilasam It fails the test Drugs Testing the date of Vaidyasala, ‘Alcohol soluble Laboratory mfg Panayamuttom, Extractive and Thiruvananthapura Nedumangadu, pH’ as per API m Thiruvananthapuram 695 561 8. CANDITRAL 100 5230123 Jan-23 Jun-25 GLENMARK THE SAMPLE Maharashtra (ITRACONAZOLE PHARMACEUTICALS LTD. DOES NOT CAPSULE B.P. 100 COMPLY WITH B P MG) REQUIREMENTS FOR DISSOLUTION TEST 9. Lytraco 200 SLP-22445 Feb-23 Jan-25 STERLIFE PHARMA PVT. THE SAMPLE Maharashtra Itraconazole LTD. DOES NOT Capsules 200 mg COMPLY WITH B P REQUIREMENTS FOR DISSOLUTION TEST THE SAMPLE IS OFFICIAL IN B P 2021 THEREFORE THE SAMPLE ISMISBRANDED VIDE SECTION 17(b) AND RULE 96 OF THE DRUGS AND COSMETICS ACT 1940 AND RULES 1945. 10. MONTOR -LC B18523001 Jan-23 Dec-24 TORQUE THE SAMPLE Maharashtra TABLET PHARMACEUTICALS DOES NOT (MONTELUKAST PVT. LTD. COMPLY WITH I P SODIUM & REQUIREMENTS LEVOCETRIZINE FOR DIHYDROCHLORI DISSOLUTION DE TABLET I.P.) TEST 11. MONTICET-L TP-7581 Sep-22 Aug-24 TICOMA PHARMACIA THE SAMPLE Maharashtra Tablets DOES NOT ( Montelukast & COMPLY WITH IP Levocetirizine REQUIREMENTS Hydrochloride FOR Tablets) DISSOLUTION TEST FOR MONTELUKAST. THE SAMPLE IS OFFICIAL IN 1 P 2018 THEREFORE THE SAMPLE IS MISBRANDED VIDE SECTION 17(b) AND RULE 96 OF THE DRUGS AND COSMETICS ACT 1940 AND RULES 1945. 12. Levocetrizine T22H370C Aug-22 Jul-24 Bajaj Formulations THE SAMPLE Maharashtra Dihydrochloride & DOES NOT Montelukast COMPLY WITH IP Sodium Tablets I.P. REQUIREMENTS Zeemont FOR DISSOLUTIONTEST FOR MONTELUKAST. 13. VolKast Kid Syrup ABS- Jan-23 Dec-24 Amentis Biotech Pvt. Ltd. CONTENT OF Maharashtra 60 ml. 2301022 MONTELUKAST AND LEVOCETIRIZINE GYDROCHLORIDE IN THE SAMPLE IS LESS (i.e. MONTELUKAST IS 10.50% AND LEVOCETIRIZINE HYDROCHLORIDE IS 71.88% OF THE STATED AMOUNT) THAN THE PERMISSIBLE LIMITS. 14. Levetiracetam T23D050A Apr-23 Mar-25 BAJAJ FORMULATIONS THE SAMPLE Maharashtra Tablets U.S.P.500 DOES NOT Mg COMPLY WITH (LEVEEG-500) USP REQUIREMENTS FOR DISSOLUTION. 15. M2 Pan-DSR CWHC-283 Oct-22 Sep-24 COSWAY THE SAMPLE Maharashtra (Pantoprazole PHARMACEUTICALS DOES NOT Gastro-resistant & COMPLY WITH IP Domperidone REQUIREMENTS Prolonged-release FOR Capsules IP) DISSOLUTION OF PANTOPRAZOLE AT ACID STAGE 16. Omeford - 40 SNT-220421 Sep-22 Aug-24 SVR HEALTHCARE (A THE CONTENT OF Maharashtra GMP Certified Company) OMEPRAZOLE IN THE SAMPLE IS LESS (l.e. 40.84% OF LABELLEDAMOUNT) THAN THE SCHEDULE V LIMITS 17. COZOL- AC1952 Jul-23 Jun-25 ALICON THE SAMPLE Maharashtra D(Omeprazole with PHARMACEUTICAL PVT DOES NOT Domperidone LTD COMPLY WITH IP Capsules) REQUIREMENTS FOR OMEPRAZOLE AND DOMPERIDONE CAPSULES FOR THE DISSOLUTION TEST (OMEPRAZOLE). THE SAMPLE IS OFFICIAL IN IP. 18. DRPLAN-DSR AC2209003A Sep-22 Aug-24 ADDII BIOTECH PVT. LTD. THE SAMPLE Maharashtra (Pantoprazole DOES NOT Gasto-resistant & COMPLY WITH IP Domperidone REQUIREMENTS Prolonged-release FOR Capsules IP) PANTOPRAZOLE AND DOMPERIDONE CAPSULES FOR THE DISSOLUTION TEST (PANTOPRAZOLE) . 19. SOFTOM-D UD2C- Apr-23 Mar-25 ULTRA DRUGS PVT. LTD. THE SAMPLE Maharashtra Omeprazole and 23252B (UNIT-II) DOES NOT Domperidone COMPLY WITH IP Capsules IP REQUIREMENTS FOR OMEPRAZOLE ANDDOMPERIDONE CAPSULES FOR THE DISSOLUTION TEST (OMEPRAZOLE). 20. OMEPRAZOLE & SPC230578 Mar-23 Feb-25 SALUS THE SAMPLE Maharashtra DOMPERIDONE C PHARMACEUTICALS DOES NOT CAPSULES COMPLY WITH IP (REMIZOLE-D) REQUIREMENTS FOR OMEPRAZOLE AND DOMPERIDONE CAPSULES FOR THE DISSOLUTION TEST (OMEPRAZOLE). 21. PANTOPRAZOLE PTRC-149 Feb-23 Jan-25 IOSIS REMEDIES PVT. THE SAMPLE Maharashtra (EC) & LTD. DOES NOT DOMPERIDONE COMPLY WITH IP (SR) CAPSULES REQUIREMENTS IP FOR (PANTIAC-DSR) PANTOPRAZOLE AND DOMPERIDONE CAPSULES FOR THE DISSOLUTION TEST (PANTOPRAZOLE) . 22. DYNACID BULH23008 Apr-23 Mar-25 Leeford Healthcare Ltd. 1) THE SAMPLE Maharashtra SUSPENSION DOES NOT (aluminium, COMPLY WITH I.P. magnesium & REQUIREMENTS simethicone oral FOR TOTAL suspension IP.) AEROBIC VIABLECOUNT IN TEST FOR MICROBIAL CONTAMINATION. 2) TOTAL AEROBIC VIABLE COUNT OF THE SAMPLE IS 20993128 CFU/GM. (1.P. LIMIT-TOTAL AEROBIC VIABLE COUNT OF THE SAMPLE - NOT MORE THAN 100 CFU/GM 23. ELTHROM-200 G-042/5045 May-23 Apr-25 ELFIN DRUGS PVT. LTD. CONTENT OF Maharashtra (Azithromycin oral AZITHROMYCIN IN suspension IP) THE SAMPLE IS 15ML LESS (72.96% OF LABELLED AMOUNT) THAN THE IP LIMIT WITH RESPECT TO ABOVE PROTOCOL. (IP LIMIT-90.0%- 110.0%) 24. Alpracan 0.5 T2455 Oct-22 Sep-25 Evolet Pharmaceutical Pvt. THE SAMPLE Maharashtra Tablets Ltd. DOES NOT (Alprazolam COMPLY WITH IP Tablets) REQUIREMENTS FOR ALPRAZOLAM TABLETS FOR THE DISSOLUTION TEST WITH RESPECT TO ABOVE PROTOCOL.25. RABEPP TABLETS ATG2K135 Nov-22 Oct-24 ANROSE PHARMA CONTENT OF Maharashtra (Rabeprazole RABEPRAZOLE Sodium Tablets IP) SODIUM IM THE SAMPLE IS LESS (65.04% OF THE LABELLED AMOUNT) THAN THE IP LIMIT WITH RESPECT TO ABOVE PROTOCOL. (IP LIMIT 90.0% - 110.0%) 26. INFI-650 TABLETS AT-100008 Dec-22 Nov-25 ABARIS HEALTHCARE THE SAMPLE Maharashtra (PARACETAMOL DOES NOT TABLETS I.P. 650 COMPLY WITH IP mg) REQUIREMENTS FOR DISSOLUTION TEST. 27. CUCID-DM CDMC501 May-23 Apr-25 TULBROS THE SAMPLE Maharashtra FORMULATIONS DOES NOT COMPLY WITH IP REQUIREMENTS FOR DISSOLUTION TEST FOR OMEPRAZOLE IN ACID STAGE. 28. Virpan-40 T-2306031A Jun-23 May-25 WHITE ENGLE THE SAMPLE Maharashtra LABORATORIES DOES NOT COMPLY WITH IP REQUIREMENTS FOR DISSOLUTION IN BUFFER STAGE. 29. Pantakos-40 CCT231092 Sep-23 Aug-25 Cent Cure Pvt Ltd. THE SAMPLE Maharashtra (Pantoprazole B DOES NOTGastro-resistant COMPLY WITH IP Tablets IP ) REQUIREMENTS FOR DISSOLUTION IN BUFFER STAGE. 30. Rosumep ASP PBWGM04 Sep-23 Aug-25 Pure & Care Healthcare THE SAMPLE Maharashtra 10/75mg Capsules Pvt. Ltd. DOES NOT COMPLY WITH IP FOR THE TEST “RELATED SUBSTANCES – ROSUVASTATIN”. NOTE: 1. NSQ data was not received as per Format & in EXCEL SHEET from State Drugs Licensing Authorities of Rajasthan (PDF format) and Orissa (PDF Format). for the Month of June, 2024 as per DCG(I) Circular dated 09.02.2024. 2. State Drugs Licensing Authorities of Andhra Pradesh, Arunachal Pradesh, Assam, Bihar, Chhattisgarh,Goa,Gujarat, Haryana, Himachal Pradesh, Manipur, Meghalaya, Mizoram, Nagaland, Odisha, Punjab, Sikkim, Tamil Nadu, Pondicherry,Telangana,Delhi,Uttarakhand, West Bengal, Andaman & Nicobar, Dadar and Nagar Haveli; Daman and Diu, Lakshadweep have not submitted any data in respect of the Not of Standard Quality (NSQ) Alert for the Month of June, 2024 as per DCG(I) Circular dated 09.02.2024.

Continue your research